(Q38245928)

31 August 2017

title

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia (English)

1 reference

31 August 2017

1 reference

1 reference

Marion Subklewe

1

1 reference

31 August 2017

Christiane Geiger

2

1 reference

31 August 2017

Felix S Lichtenegger

3

1 reference

31 August 2017

Miran Javorovic

4

1 reference

31 August 2017

Gunnar Kvalheim

5

1 reference

31 August 2017

Dolores J Schendel

6

1 reference

31 August 2017

Iris Bigalke

7

1 reference

31 August 2017

publication date

4 September 2014

1 reference

Cancer Immunology, Immunotherapy

31 August 2017

published in

1 reference

31 August 2017

volume

63

1 reference

31 August 2017

issue

10

1 reference

31 August 2017

page(s)

1093-1103

1 reference

Acute myeloid leukaemia in adults

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Current strategies in immunotherapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Peptide vaccines for patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Fast generation of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Signals required for programming effector and memory development by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Clinical cancer vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Dendritic cells in cancer immunotherapy clinical trials: are we making progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Cancer immunotherapy with mRNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Humanized mice in translational biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Characterization of chronic myeloid leukemia stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Epitope dominance, competition and T cell affinity maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1600-5

10.1007/S00262-014-1600-5

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1036812256

0 references

1 reference